Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women
A new analysis suggests that Evista (raloxifene) reduces the risk of MI and stroke in postmenopausal women.
This "selective estrogen" has some advantages for preventing or treating osteoporosis in postmenopausal women.
Both Evista and estrogen increase bone density.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote